Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook Therapeutics, Inc.

https://outlooktherapeutics.com

Latest From Outlook Therapeutics, Inc.

AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Deals Gene Therapy

Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

Review Pathway Europe

Clinical Hold Halts Larimar’s Friedrich’s Ataxia Candidate And Financing

Looking to develop the first drug therapy for FA, Larimar gets US FDA hold due to deaths in non-human primate study. This alters clinical development timelines and fundraising plans for the firm.

Clinical Trials Drug Safety

First Ophthalmic Formulation Of Bevacizumab Among New Filings At EMA

Using the cancer drug off-label to treat wet AMD has been controversial.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Oncobiologics, Inc.
UsernamePublicRestriction

Register